Phase 2 N=21 Stem Cells in Rapidly Evolving Active Multiple Sclerosis
Multiple Sclerosis
Primary: Number of Adverse Events Assessed by CTCAE v4.0 — 5; 0 total events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=66 Should I Have an Elective Induction?
Labor, Induced · Patient Preference
Primary: Recruitment Rate — 66 Participants
N/A N=252 Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
COPD
Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001
Phase 1 N=33 A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
N/A N=60 OA Clinic-Community CARE Model
Osteoarthritis, Knee · Osteoarthritis, Hip · Overweight
Primary: Change From Baseline to Month 6 in Western Ontario and McMasters Universities Osteoarthritis (WOMAC) Total Score — -7.8; 3.2 units on a scale — p=0.019
Phase 2 N=155 Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
Non Small Cell Lung Cancer Metastatic
Primary: Progression Free Survival (PFS) — 15.4; 12.3 months — p=0.84
N/A N=18 Development of a Multifunctional Rehabilitation Device for Persons With Parkinson's Disease
Parkinson Disease
Primary: (Aim 1) Mean of User Acceptance Questionnaire (UAQ) Part 1 Total Scores — 7.28 score on a scale
N/A N=109 Remote Guided Caffeine Reduction
Caffeine Dependence · Anxiety · Sleep Disturbance
Primary: Number of Participants With Treatment Retention as Assessed by Number of Participants With Completed Assessments — 51; 51; 50; 46 Participants
N/A N=59,997 Social Norms, Messengers, and Processing Fluency to Increase Hypertension Medication Adherence
Medication Adherence · Hypertension
Primary: Average End-of-year Adherence Level — 0.81; 0.81; 0.81; 0.81 proportion of days covered
N/A N=600 Evaluating Oral Nutritional Supplements on Children's Nutritional Status and Digestive Health in Vietnam.
Undernutrition · Wasting · Malnourished
Primary: Improvement of Digestive Disorders and Anorexia Nervosa — 219; 212; 175; 155 participants
Phase 2 N=97 Onsite Buprenorphine Treatment at Syringe Exchange Programs
Opiate Addiction
Primary: Buprenorphine Engagement — 19; 19 Participants — p=0.94
Phase 4 N=30 Cardiovascular Effects of Adderall in Healthy Adults.
Hemodynamics · Cardiovascular System
Primary: Systolic Blood Pressure — 116; 116; 126; 115 mmHg
N/A N=232 Nurse-To-Family Telehealth
Pediatric Disorder
Primary: Assignment Adherence — 4; 76 Participants
Phase 4 N=29 Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
Parkinson Disease Psychosis
Primary: Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score — 14.0 score on a scale — p=<0.0001
Phase 1 N=56 A Study of LY3493269 in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to…